The firms will provide access to tumor profiling tests for both tissue and plasma samples, specifically PGDx's elio tissue complete and elio plasma resolve assays.
Using single-cell and bulk RNA sequence data, investigators identified four pathway-based GBM subtypes, including a mitochondrial subtype that appears to respond to related inhibitors.
The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.
The firms will use Resolution's ctDx liquid biopsy technology to find non-small cell lung cancer patients who may benefit from Mirati's KRAS G12C inhibitor therapy.
Through the R&D collaboration with Karolinska's NextGenNK Center, the firm hopes to advance its ROR1-targeting CAR T cell and CAR NK cell treatments into the clinic.
The researchers identified molecular subtypes of head and neck cancer that could be susceptible to CDK inhibitor, anti-EGFR antibody, or immunotherapy treatments.
HalioDx operates a CLIA-certified lab through which OncoDNA will provide it molecular testing services to drugmakers studying precision cancer therapies.
The firm hopes to begin evaluating its irreversible menin/MLL inhibitor in clinical trials for both solid and blood cancers in by the second half of 2021.
The company will put funds toward a Phase I clinical trial of CT-0508, a HER2-targeted CAR macrophage therapy, which recently began enrolling patients.
The company has acquired a SHP2 inhibitor and an ERK inhibitor through two worldwide licensing agreements and has begun testing the former in the clinic.
Hologic said that Biotheranostics' PCR-based gene expression tests have been validated in large studies in areas of oncology with high growth potential.
Opdivo plus chemotherapy extended survival for gastric cancer patients whose tumors expressed PD-L1 and in all comers in the Phase III CheckMate-649 trial.
